From the Sorbonne Université, Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, AP-HP Pitie-Salpetriere Hospital, Paris, France (Genser, Lim, Goumard, Scatton).
Department of Digestive, Endocrine, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Trousseau Hospital, Tours Regional University Hospital, Tours, France (Barbier).
J Am Coll Surg. 2022 Aug 1;235(2):159-171. doi: 10.1097/XCS.0000000000000221. Epub 2022 Apr 8.
Liver surgeons need to know the expected outcomes of laparoscopic liver resection (LLR) in obese patients.
The purpose of the present study is to assess morbidity, mortality and textbook outcomes (TO) after LLR in obese patients.
This is a French multicenter study of patients undergoing LLR between 1996 and 2018. Obesity was defined by a BMI at or above 30 kg/m 2 . Short-term outcomes and TO were compared between obese (ob) and nonobese (non-ob) patients. Factors associated with severe morbidity and TO were investigated.
Of 3,154 patients included, 616 (19.5%) were obese. Ob-group patients had significantly higher American Society of Anesthesiologists (ASA) score and higher incidence of metabolic syndrome and chronic liver disease and were less likely to undergo major hepatectomy. Mortality rates were similar between ob and non-ob groups (0.8 vs 1.1%; p = 0.66). Overall morbidity and hospital stay were significantly increased in the ob group compared with the non-ob group (39.4 vs 34.7%, p = 0.03; and 9.5 vs 8.6 days, p = 0.02), whereas severe 90-day morbidity (at or above Clavien-Dindo grade III) was similar between groups (8% in both groups; p = 0.90). TO rate was significantly lower for the ob group than the non-ob group (58.3 vs 63.7%; p = 0.01). In multivariate analysis, obesity did not emerge as a risk factor for severe 90-day morbidity but was associated with a lower TO rate after LLR (odds ratio = 0.8, 95% CI 0.7-1.0; p = 0.03).
LLR in obese patients is safe and effective with acceptable mortality and morbidity. Obesity had no impact on severe morbidity but was a factor for failing to achieve TO after LLR.
肝外科医生需要了解肥胖患者腹腔镜肝切除术(LLR)的预期结果。
本研究旨在评估肥胖患者接受 LLR 后的发病率、死亡率和教科书结果(TO)。
这是一项法国多中心研究,纳入了 1996 年至 2018 年间接受 LLR 的患者。肥胖定义为 BMI 为 30kg/m 2 或以上。比较肥胖(ob)和非肥胖(non-ob)患者的短期结果和 TO。研究了与严重发病率和 TO 相关的因素。
在纳入的 3154 名患者中,有 616 名(19.5%)为肥胖患者。ob 组患者的美国麻醉医师协会(ASA)评分更高,代谢综合征和慢性肝病的发生率更高,更不可能接受主要肝切除术。ob 组和 non-ob 组的死亡率相似(0.8%比 1.1%;p=0.66)。ob 组的总体发病率和住院时间明显高于 non-ob 组(39.4%比 34.7%,p=0.03;9.5 天比 8.6 天,p=0.02),而两组 90 天严重发病率(Clavien-Dindo 分级 III 或以上)相似(两组均为 8%;p=0.90)。ob 组的 TO 率明显低于 non-ob 组(58.3%比 63.7%;p=0.01)。多变量分析显示,肥胖不是 90 天严重发病率的危险因素,但与 LLR 后 TO 率降低相关(比值比=0.8,95%CI 0.7-1.0;p=0.03)。
肥胖患者的 LLR 安全有效,死亡率和发病率可接受。肥胖对严重发病率没有影响,但会降低 LLR 后的 TO 率。